Skip to main content

Quinacrine Disease Interactions

There are 4 disease interactions with quinacrine.

Major

Aminoquinolines (applies to quinacrine) porphyria

Major Potential Hazard, Moderate plausibility.

The use of aminoquinolines in patients with porphyria may exacerbate the condition. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.

References

  1. "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals PROD (2002):
  2. Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995): 548-51
  3. "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc (2022):
Moderate

Aminoquinolines (applies to quinacrine) glucose-6-PD deficiency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: G-6-PD Deficiency

Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Therapy with aminoquinolines should be administered cautiously in these patients. Blood cell counts and hemoglobin determinations should be performed regularly. Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.

References

  1. "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals PROD (2002):
  2. "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc (2022):
Moderate

Aminoquinolines (applies to quinacrine) hepatotoxicity

Moderate Potential Hazard, Low plausibility. Applicable conditions: Liver Disease, Alcoholism

Aminoquinolines may concentrate in the liver. Isolated cases of abnormal liver function and fulminant hepatic failure have been reported. Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs. Periodic evaluation of hepatic function should be performed during prolonged therapy.

References

  1. "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals PROD (2002):
  2. Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995): 548-51
  3. "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc (2022):
  4. Grossman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E "Mefloquine-induced acute hepatitis." Pharmacotherapy 20 (2000): 1517-9
View all 4 references
Moderate

Aminoquinolines (applies to quinacrine) psoriasis

Moderate Potential Hazard, Moderate plausibility.

The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.

References

  1. Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981): 546-7
  2. Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989): 1400
  3. Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991): 463-5
  4. Kuflik EG "Effect of antimalarial drugs on psoriasis." Cutis 26 (1980): 53-5
  5. Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992): 211-2
  6. "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals PROD (2002):
  7. "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc (2022):
View all 7 references

Quinacrine drug interactions

There are 12 drug interactions with quinacrine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer